



RaQualia Pharma Inc.

Launch of Tegoprazan in Latin American Countries

Nagoya, Japan, December 12, 2024 – RaQualia Pharma Inc. (headquartered in Nagoya; President & CEO: Hirobumi Takeuchi, “RaQualia”) announced today that one of its sublicensees, Laboratorios Carnot (Headquarters: Mexico City, Mexico; “Carnot”), started the product sales in Mexico of tegoprazan, a gastric acid secretion inhibitor, which was licensed through HK inno. N Corporation (headquartered in Seoul, South Korea, “HK inno.N”).

Tegoprazan is a potassium-competitive acid blocker (P-CAB), a new-generation treatment for gastroesophageal reflux disease. P-CABs have a different mechanism of action from proton pump inhibitors (PPIs), the first-line therapy for gastroesophageal reflux disease, and suppress gastric acid secretion more rapidly and persistently than PPIs.

RaQualia and HK inno.N entered into an exclusive license agreement for developing, marketing, and manufacturing tegoprazan with sublicensing rights. HK inno.N and its business partners worldwide have been conducting business activities for tegoprazan. In Latin America, HK inno.N concluded license agreements with two companies, including Carnot, and the business activities related to the development and marketing of tegoprazan are underway in 18 countries. Carnot launched tegoprazan products in Mexico and Peru under the brand name Ki-CAB® in 2023 and in Chile and Colombia in September and October of this year. Ki-CAB® has now become available in five new countries in Latin America: the Dominican Republic, Nicaragua, Honduras, Guatemala, and El Salvador. As a result, tegoprazan products are marketed in 15 countries worldwide. Carnot is actively marketing Ki-CAB® in its territory. In Mexico, where Carnot first launched the product, Ki-CAB® ranked third in peptic ulcer market share and is expected to grow further.

Under the license agreement with HK inno.N, RaQualia has the right to receive a portion of the revenues earned by HK inno.N from sublicensees. Although RaQualia will receive no lump-sum payment due to this product launch, RaQualia believes that expanding tegoprazan marketing in more countries will enhance RaQualia’s business earnings and corporate value over the medium to long term. RaQualia will continue to strengthen its partnership with HK inno.N, providing continuous support for the development and sublicensing to expand the options for gastric acid-related diseases, thereby making further contributions to improving patients’ quality of life.

###

RaQualia Pharma, Inc. Media Contact:

RaQualia Pharma, Inc.

8F Meieki Southside Square, 1-21-19 Meieki Minami Nakamura-ku, Nagoya 450-0003, Japan

Tel: +81-446-6100

Email: ask@raqualia.com